NanO₂
Glioblastoma (as a radiosensitizer)
Key Facts
About NuvOx Therapeutics
NuvOx Therapeutics is advancing NanO₂, a novel oxygen therapeutic, through mid-stage clinical trials targeting conditions where hypoxia is a key driver of pathology. The company has active Phase IIb trials in glioblastoma and stroke, with a Phase Ib trial in respiratory distress planned, supported by significant non-dilutive funding from U.S. and U.K. government agencies. Its platform has demonstrated therapeutic effects in over 30 animal studies across seven indications, positioning it to address high-unmet-need areas in oncology, neurology, and critical care. NuvOx remains a private, pre-revenue company leveraging grant and partnership capital to de-risk its clinical programs.
View full company profileAbout NuvOx Therapeutics
NuvOx Therapeutics is advancing NanO₂, a novel oxygen therapeutic, through mid-stage clinical trials targeting conditions where hypoxia is a key driver of pathology. The company has active Phase IIb trials in glioblastoma and stroke, with a Phase Ib trial in respiratory distress planned, supported by significant non-dilutive funding from U.S. and U.K. government agencies. Its platform has demonstrated therapeutic effects in over 30 animal studies across seven indications, positioning it to address high-unmet-need areas in oncology, neurology, and critical care. NuvOx remains a private, pre-revenue company leveraging grant and partnership capital to de-risk its clinical programs.
View full company profileAbout NuvOx Therapeutics
NuvOx Therapeutics is advancing NanO₂, a novel oxygen therapeutic, through mid-stage clinical trials targeting conditions where hypoxia is a key driver of pathology. The company has active Phase IIb trials in glioblastoma and stroke, with a Phase Ib trial in respiratory distress planned, supported by significant non-dilutive funding from U.S. and U.K. government agencies. Its platform has demonstrated therapeutic effects in over 30 animal studies across seven indications, positioning it to address high-unmet-need areas in oncology, neurology, and critical care. NuvOx remains a private, pre-revenue company leveraging grant and partnership capital to de-risk its clinical programs.
View full company profileAbout NuvOx Therapeutics
NuvOx Therapeutics is advancing NanO₂, a novel oxygen therapeutic, through mid-stage clinical trials targeting conditions where hypoxia is a key driver of pathology. The company has active Phase IIb trials in glioblastoma and stroke, with a Phase Ib trial in respiratory distress planned, supported by significant non-dilutive funding from U.S. and U.K. government agencies. Its platform has demonstrated therapeutic effects in over 30 animal studies across seven indications, positioning it to address high-unmet-need areas in oncology, neurology, and critical care. NuvOx remains a private, pre-revenue company leveraging grant and partnership capital to de-risk its clinical programs.
View full company profile